[{"from": "human", "value": "What can you tell me about this molecule? [C][C][=Branch1][C][=O][N][C][C][Branch2][Ring2][Branch2][C][=C][Ring1][Branch1][C][=C][C][=C][Ring1][=Branch1][S][C][=N][C][=C][Branch1][=Branch1][N][=C][Ring1][=Branch1][N][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][O][C][C@H1][Ring1][#Branch1][N][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation."}]